Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Autologous Hematopoietic Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades.

Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P.

Biol Blood Marrow Transplant. 2019 Feb 20. pii: S1083-8791(19)30140-5. doi: 10.1016/j.bbmt.2019.02.015. [Epub ahead of print]

PMID:
30794931
2.

Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.

Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN.

J Clin Oncol. 2013 Sep 1;31(25):3100-9. doi: 10.1200/JCO.2012.46.0188. Epub 2013 Jul 29.

3.

A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.

Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M.

Bone Marrow Transplant. 2015 Nov;50(11):1416-23. doi: 10.1038/bmt.2015.177. Epub 2015 Aug 3.

4.

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.

Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1163-1171. doi: 10.1016/j.bbmt.2017.12.771. Epub 2017 Dec 11.

PMID:
29242111
5.

Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.

Czyz A, Lojko-Dankowska A, Dytfeld D, Nowicki A, Gil L, Matuszak M, Kozlowska-Skrzypczak M, Kazmierczak M, Bembnista E, Komarnicki M.

Med Oncol. 2013;30(3):611. doi: 10.1007/s12032-013-0611-y. Epub 2013 May 24.

6.

Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center.

Huang H, Jiang Y, Wang Q, Guo L, Jin Z, Fu Z, Han Y, Sun A, Liu W, Ruan J, Wu D.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1393-1397. doi: 10.1016/j.bbmt.2017.04.021. Epub 2017 May 3.

7.

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.

Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M.

Br J Haematol. 2016 Jul;174(2):235-48. doi: 10.1111/bjh.14046. Epub 2016 Mar 15.

8.

High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.

Lewin J, Dickinson M, Voskoboynik M, Collins M, Ritchie D, Toner G.

Intern Med J. 2014 Aug;44(8):771-8. doi: 10.1111/imj.12486.

PMID:
24893627
9.

Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.

Czyz A, Romejko-Jarosinska J, Helbig G, Knopinska-Posluszny W, Poplawska L, Piatkowska-Jakubas B, Hawrylecka D, Nasilowska-Adamska B, Dytfeld D, Lojko-Dankowska A, Kopinska A, Boguradzki P, Walewski J, Kyrcz-Krzemien S, Hellmann A, Komarnicki M.

Ann Hematol. 2013 Jul;92(7):925-33. doi: 10.1007/s00277-013-1716-2. Epub 2013 Mar 8.

10.

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Fléchon A, Geoffrois L, Caty A, Soares DG, de Revel T, Fizazi K, Gligorov J, Micléa JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP.

Ann Oncol. 2014 Sep;25(9):1775-82. doi: 10.1093/annonc/mdu198. Epub 2014 Jun 3.

PMID:
24894084
11.

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.

Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1893-1899. doi: 10.1016/j.bbmt.2016.07.007. Epub 2016 Aug 2.

12.

Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation.

Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL.

Biol Blood Marrow Transplant. 2019 Jan 30. pii: S1083-8791(19)30086-2. doi: 10.1016/j.bbmt.2019.01.028. [Epub ahead of print]

PMID:
30708189
13.

High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.

Adra N, Abonour R, Althouse SK, Albany C, Hanna NH, Einhorn LH.

J Clin Oncol. 2017 Apr 1;35(10):1096-1102. doi: 10.1200/JCO.2016.69.5395. Epub 2016 Nov 21.

14.

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.

Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ.

Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72.

15.

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L.

Ann Oncol. 2015 Oct;26(10):2125-32. doi: 10.1093/annonc/mdv310. Epub 2015 Jul 21. Erratum in: Ann Oncol. 2015 Dec;26(12):2507-8.

16.

Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.

Czyz A, Romejko-Jarosinska J, Knopinska-Posluszny W, Nowicki A, Lojko-Dankowska A, Gil L, Dytfeld D, Walewski J, Hellmann A, Komarnicki M.

Leuk Lymphoma. 2013 May;54(5):973-8. doi: 10.3109/10428194.2012.734612. Epub 2012 Oct 29.

PMID:
23025342
17.

Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.

Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1255-64. doi: 10.1016/j.bbmt.2011.12.581. Epub 2011 Dec 23.

18.

Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

Narayan V, Gunnarsson O, Hwang WT, Squillante CM, Nathanson KL, Stadtmauer EA, Vaughn DJ.

Clin Genitourin Cancer. 2016 Dec;14(6):524-529. doi: 10.1016/j.clgc.2016.03.015. Epub 2016 Mar 24.

PMID:
27083130
19.

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P.

J Clin Oncol. 2015 Nov 10;33(32):3741-9. doi: 10.1200/JCO.2015.62.4015. Epub 2015 Sep 14.

20.

Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG.

Biol Blood Marrow Transplant. 2011 Jul;17(7):1051-7. doi: 10.1016/j.bbmt.2010.11.004. Epub 2010 Nov 10.

Supplemental Content

Support Center